Unichem Laboratories Ltd. — Capital/Financing Update 2022

Feb 28, 2022

==> picture [190 x 43] intentionally omitted <==

February 28, 2022

Department of Corporate Services Bombay Stock Exchange, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001.

Mr. Hari K.

Asst. Vice President - Operations National Stock Exchange of India Ltd. Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051.

Ref: BSE Scrip Code – 506690: NSE Symbol – UNICHEMLAB

Dear Sir,

Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the press release pertaining to receipt of ANDA approval from United States Food and Drug Administration (USFDA) for Unichem’s Divalproex Sodium Extended-Release Tablets USP, 250 mg and 500 mg.

For Unichem Laboratories Limited

PRADEEP Digitally signed by PRADEEP BHANDARI BHANDARI Date: 2022.02.28 09:58:07 +05'30' Pradeep Bhandari Head- Legal & Company Secretary

==> picture [189 x 32] intentionally omitted <==

Registered Office: Unichem Bhavan, Prabhat Estate, Off S. V. Road Jogeshwari (West), Mumbai – 400 102, Maharashtra, India.

==> picture [190 x 43] intentionally omitted <==

Mumbai, Monday, February 28, 2022

PRESS RELEASE

Unichem Laboratories Limited is pleased to announce that it has received ANDA approval for its Divalproex Sodium Extended-Release Tablets USP, 250 mg and 500 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Depakote[®] ER (Divalproex Sodium) Extended-Release Tablets 250 mg and 500 mg, of AbbVie Inc.

Divalproex Sodium Extended-Release Tablets are indicated for treatment of acute manic or mixed episodes associated with bipolar disorder, as monotherapy and adjunctive therapy and prophylaxis of migraine headaches. The product will be commercialized from Unichem’s Goa Plant.

About Unichem Laboratories Limited

Unichem Laboratories Limited is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in several markets across the world. In India, The Company has strong skills in product development, process chemistry and manufacturing complex API as well as dosage forms. More information about the Company can be found at www.unichemlabs.com

For more information please contact:

Mr. Pradeep Bhandari E-mail: pradeep.bhandari@unichemlabs.com

Disclaimer:

This press release includes forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ serially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.

==> picture [189 x 32] intentionally omitted <==

Registered Office: Unichem Bhavan, Prabhat Estate, Off S. V. Road Jogeshwari (West), Mumbai – 400 102, Maharashtra, India.